Check out our news

Get our newsletters

Published on the 9 March 2021

Alzheimer’s Disease – a new preclinical model

As announced a few weeks ago, we tested the effects of donepezil (DPZ) in our Alzheimer's disease model, induced by the administration of beta-amyloid oligomers 1-42. We have shown that memory disorde…

Company
Published on the 8 March 2021

BB@C: a new translational research institute for the clinical solutions of tomorrow – in partnership with STROK@LLIANCE and ETAP-Lab

The Blood and Brain @ Caen-Normandy Institute (BB@C) is a Scientific Interest Group aiming to develop the clinical solutions of the future. Connecting 9 start-ups and preclinical CROs, 4 university re…

Company
Published on the 23 February 2021

New whole-body plethysmography system (Buxco, DSITM)

SYNCROSOME has acquired a new whole-body plethysmography system (Buxco, DSITM). Whole-body plethysmography is used to measure respiratory parameters in conscious unrestrained animals. This sy…

Science and innovation
Published on the 22 January 2021

New model for Alzheimer’s Disease – First batch of data!

The toxicity of our beta-amyloid peptide oligomers is confirmed in vivo in elderly mice After several months’ development, several replicated studies show that oligomers of A-beta peptides (whose neur…

Science and innovation
Published on the 30 November 2020

Approval for the first psychobiotics: ETAP-Lab is proud to have played a role

In partnership with Lallemand Health Solutions, Aspen Farmacêutica is bringing the first psychobiotic formulation for the gut-brain axis to the Brazilian market. The two finished products are Probid …

Company
Published on the 16 November 2020

EWMA: Presentation of the results of work we conducted for URGO laboratories

Preclinical research carried out in a rat skin healing model that has shown the efficacy of a sucrose octasulfate dressing (UrgoStart) will be presented at the EWMA Digital Congress on November 18 and…

Science and innovation Events
Published on the 10 November 2020

Our tau oligomer toxicity – a new tool for drug screening

The toxicity of the tau oligomers produced by ETAP-Lab can be reversed by using BDNF on primary rat neuron cultures. BNDF applied at the same time as tau oligomers significantly and reproducibly redu…

Science and innovation
Published on the 19 October 2020

Tau oligomer toxicity – our first data!

The new tau oligomers produced by ETAP-Lab show reproducible and dose-dependent toxicity on rodent primary neuron cultures. Promising and repeatedly replicated data show that tau oligomers exhibit …

Science and innovation

Explore our scientific resources and browse posters…

Explore our resources